Table 3.
IOP and antiglaucoma medication after MMC-TLE in UG and POAG
| Follow−up (mo) | UG | POAG | ||
|---|---|---|---|---|
| IOP (mmHg) | Medications | IOP (mmHg) | Medications | |
| 1 | 10.8 ± 4.4 | 0.0 ± 0.0 | 11.6 ± 4.7 | 0.1 ± 0.4 |
| 6 | 11.0 ± 3.8 | 0.2 ± 0.5∗ | 11.5 ± 4.0 | 0.7 ± 1.0 |
| 12 | 11.7 ± 4.2 | 0.3 ± 0.8∗∗ | 12.2 ± 3.8 | 0.8 ± 1.1 |
| 18 | 11.2 ± 4.2 | 0.3 ± 0.7∗∗ | 12.2 ± 3.4 | 1.1 ± 1.2 |
| 24 | 11.0 ± 4.0 | 0.5 ± 1.1∗∗ | 12.1 ± 3.1 | 1.3 ± 1.3 |
| 30 | 10.8 ± 4.7∗ | 0.6 ± 1.1∗∗ | 12.5 ± 3.0 | 1.4 ± 1.3 |
| 36 | 11.9 ± 7.0 | 0.7 ± 1.2∗∗ | 12.1 ± 3.1 | 1.5 ± 1.3 |
| 42 | 11.4 ± 4.6 | 0.9 ± 1.4 | 11.9 ± 3.3 | 1.5 ± 1.4 |
| 48 | 10.5 ± 4.1 | 1.1 ± 1.5 | 11.5 ± 3.2 | 1.6 ± 1.4 |
| 54 | 10.9 ± 3.9 | 1.3 ± 3.9 | 11.9 ± 3.3 | 1.5 ± 1.4 |
| 60 | 10.6 ± 4.0 | 1.3 ± 1.7 | 11.7 ± 3.9 | 1.6 ± 1.4 |
| 66 | 10.3 ± 3.6 | 1.6 ± 1.6 | 12.0 ± 4.4 | 1.7 ± 1.5 |
| 72 | 10.8 ± 4.8 | 1.6 ± 1.8 | 11.0 ± 3.1 | 1.8 ± 1.6 |
| 78 | 10.0 ± 3.8 | 1.7 ± 1.7 | 11.9 ± 4.5 | 1.7 ± 1.7 |
| 84 | 10.5 ± 3.9 | 1.1 ± 1.3 | 11.6 ± 3.8 | 1.7 ± 1.7 |
| 90 | 10.4 ± 4.3 | 1.1 ± 1.3 | 11.5 ± 4.0 | 1.8 ± 1.8 |
| 96 | 9.2 ± 3.1 | 0.9 ± 1.1 | 11.1 ± 3.0 | 1.9 ± 1.6 |
| 102 | 8.8 ± 2.9 | 0.6 ± 1.0∗ | 11.8 ± 5.4 | 2.2 ± 1.7 |
| 108 | 10.1 ± 3.7 | 0.5 ± 1.1∗ | 13.1 ± 5.5 | 2.7 ± 1.6 |
| 114 | 9.7 ± 5.4 | 0.2 ± 0.4∗ | 12.6 ± 6.2 | 2.4 ± 1.7 |
| 120 | 13.0 ± 5.2 | 0.2 ± 0.4∗ | 10.6 ± 1.2 | 2.6 ± 1.5 |
UG: uveitic glaucoma. POAG: primary open angle glaucoma. IOP: intraocular pressure (mean ± standard deviation). “Medications” indicates the number of different antiglaucoma medications applied regardless of their concentration and frequency. (∗P < 0.05, ∗∗P < 0.01 Student's t-test).